LAA Closure Devices: Reaching Critical Mass?
Transcatheter LAA closure devices are starting to amass the level of data required to demonstrate their safety and effectiveness, and, if all goes well, the long-awaited FDA approval of the first such device – Boston Scientific’s Watchman – could finally occur sometme next year. Although LAA closure devices have already taken off in some European countries, US physicians continue to struggle with lingering uncertainties, about the learning curve, procedural safety and how LAA closure will stack up against newer anticoagulant drugs. Regardless of how these issues are eventually resolved, industry leaders see a big opportunity for a successful device in the LAA closure space, with market estimates of $1 billion considered conservative by some.
You may also be interested in...
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.
DePuy settles bulk of U.S. ASR suits. Tandem Diabetes closes $138 million IPO. AtriCure gets go-ahead for new AtriClip stroke. More news.
The PREVAIL study of Boston Scientific’s Watchman left atrial appendage (LAA) closure device was primarily positive, but will it be enough to win FDA approval for the device?